Tecarium Topotecan Injection IP 2.5 mg is a prescription oncology medicine identified as containing Topotecan 2.5 mg per vial.

Topotecan is a cytotoxic anticancer medicine classified as a topoisomerase I inhibitor.

It interferes with DNA replication by stabilizing the topoisomerase I-DNA complex, preventing the normal repair of single-strand DNA breaks.

Topotecan is used in selected treatment settings for recurrent ovarian cancer, relapsed small cell lung cancer and persistent, recurrent or metastatic cervical cancer.

Serious neutropenia, thrombocytopenia and anemia may occur.

The stated 2.5 mg vial strength does not establish the prescribed patient dose. Dosing depends on the cancer indication, treatment protocol, body surface area, renal function and blood counts.

The exact formulation of Tecarium—whether a powder requiring reconstitution or a solution requiring dilution—must be confirmed from its approved product documentation.

The manufacturer, concentration, vial volume, excipients, storage conditions and approved indications must also be verified.

The product name includes IP (Indian Pharmacopoeia). Compliance with the applicable pharmacopoeial standard must be supported by manufacturer documentation.

Marketed by Essentials Emporium Enterprises, Tecarium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features